Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.

Mild Cognitive Impairment

Dementia

bosutinib

Neurological Associates of West LA

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias

Outcome goal to determine safety and tolerability of study medication

Sheldon Jordan

Neurologist

Neurological Associates of West Los Angeles

Pfizer

30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient

Aneurysmal Subarachnoid Hemorrhage

30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage

erythropoietin beta

Department of Neurosurgery, Addenbrooke's Hospital

Erythropoietin Therapy for Subarachnoid Hemorrhage

Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage

hydrocephalus/tyrosine

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Erythropoietin Therapy for Subarachnoid Hemorrhage

科學支持的最完整的草藥數據庫